big pharma
-
4 Sep
More speciality drugs are coming onto the market than ever before. Why?
The number of drugs picking up a designation from regulators — first treatments or speciality drugs — across the European Union, the US, and Japan have risen by 117 percent in 10 years.
-
9 Aug
Pharmaceutical scandals: US states are suing the OxyContin manufacturer
The US states of New Hampshire and South Carolina are suing Purdue Pharma, the manufacturer of OxyContin for its role in the opioid crisis.
-
4 Jul
Humira — the highest gross-selling drug in the world — isn’t done yet
Humira has set a record for the highest gross-selling drug in the world and contributed 63 percent to AbbVie’s revenue in 2016 alone and expectations are high the blockbuster drug will continue to perform.
-
29 Jun
Which class of drugs is set to have the biggest impact on the cancer market?
Cancer therapy was historically dominated by chemotherapy and hormonal therapies, but now a new drug class is poised to seize a market share of more than $35bn.
-
28 Jun
Sanofi is about to explode into the global dermatology market
Over the next few years Sanofi will go from being an also-ran in the dermatology arena to being a major player, thanks to the performance of a groundbreaking new drug.
-
27 Jun
Will a Brexit Health Alliance be able to protect the UK medical industry?
In the lead up to the UK’s departure from the EU, efforts are being made to ensure the stability of the healthcare and pharmaceutical industries.
-
31 May
The Great British Brexodus: is the UK facing a Brexit brain drain?
As divorce talks between the UK and the European Union get underway, the country could soon be deprived of some of its best scientific minds.
-
26 May
Antibiotic resistance: Could we be looking at the death of medicine?
Heart surgery, prenatal care, organ transplants, and blood transfusions.
-
19 May
Licensing deals are dominating the pharmaceutical landscape
In recent years licensing deals have dominated the pharmaceutical industry.
-
4 May
In less than ten years the number of biosimilar trials has grown by more than 1,000 percent
Biosimilar trials — testing an almost identical copy of a drug originally manufactured by a different company — have exploded in recent years.
-
3 May
How will Brexit change the pharma industry?
Since the UK triggered Article 50 — the formal European Union exit clause — in March the pharma industry has been closely watching where the European Medicines Agency (EMA) is going to relocate.
-
26 Apr
Relocating the EMA is bad news for the pharma industry and the health of 500m Europeans
One of the many issues that needs to be negotiated in the wake of British prime minister Theresa May’s triggering of Article 50 is the location of the European Medicines Agency (EMA).
-
24 Apr
Could Botox be used to battle depression?
Depression is the leading cause of disability worldwide, affecting over 300m people – but less than half of them are getting effective treatment.
-
21 Apr
Pharma price hiking: Buckle up, there are more on the way
Drug development is a lengthy, complicated and costly process, with a high rate of attrition.
-
20 Apr
China’s now a bigger pharma market than Japan and it’s still growing
In developed markets, especially the US, pharmaceutical companies are facing a period of uncertainty, with pricing and reimbursements concerns causing significant barriers to revenue potential.
-
10 Apr
Transplants are heading into the future; the wider industry needs to catch up
As the world’s first human head transplant rapidly approaches, it’s time to face the implications this could have for the future of surgery and pharma therapy.
-
3 Apr
Which big pharma companies are going to be making the most from oncology in 2021?
Well-established drug development powerhouses Roche, Celgene, and Novartis are the biggest pharma firms by oncology revenue right now and are set to hold onto the top spots over the next five years.
-
17 Mar
Pharmacoeconomics: a crushing reality in today’s industry
Times are tough in the healthcare industry and the rise of pharmacoeconomics — when the value of one pharmaceutical drug or drug therapy is compared to another — is not making life any easier for big pharma.
-
14 Feb
Trump: pharma friend or foe?
The pharmaceutical industry lies in a cloud of uncertain future policies.
-
31 Jan
Superbugs will kill 10m people per year by 2050 unless things change
Drug-resistant so-called superbugs kill at least 700,000 worldwide each year and deaths are expected to rise to 10m per year by 2050, according to economist Jim O’Neill.
-
19 Jan
Will Trump break our hearts?
Over the past few months, there has been a great deal of speculation around what kind of impact Donald Trump‘s presidency will have on healthcare and the pharmaceutical industry.
-
12 Jan
Japan’s Takeda is buying Ariad Pharma for $5.2bn — Is this deal a bellwether for the biotech industry in 2017?
Given the scarcity of commercially-ready oncology assets, cancer drugs are appealing to big pharma with lots of cash and high prices are being paid for hopeful products.